The United Kingdom and the United States have finalized a landmark trade agreement that will keep zero import taxes on British pharmaceutical shipments entering the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to increase expenditure on pharmaceuticals through the NHS. This move guarantees that import taxes on these crucial exports will remain at zero for a timeframe of the next three years.
This development follows previous statements to hike duties on branded pharmaceutical imports, with potential rates floated reaching one hundred percent.
"This arrangement with the Britain reinforces the international landscape for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. medicine commerce," a release noted.
Commercial Impact
Pharmaceuticals represent one of the the United Kingdom's biggest export categories to the America, which is by far the primary destination for leading UK drugmakers.
Export figures show that in the year leading up to September, the UK sold pharmaceutical products worth billions to the US. This value represented 17.4% of total UK exports in that period.
"This deal protects jobs, boosts funding and sets the stage for the UK to establish itself as a global hub for medical research," a government official commented.
Detailed British Pledges
The deal involves several specific commitments from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to control costs will be capped at 15%. In the past, refunds topped 20%.
Industry Background
The deal follows a long-running dispute between the drug companies and the British authorities over spending levels and approval rates.
These tensions were intensified by claims that American customers were paying a premium for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar expansions have been directed toward US facilities.
One official publicly accepted that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the past decade.
